News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Acambis PLC Announces Research Update
November 15, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Acambis plc's (" Acambis") (LSE: ACM, NASDAQ: ACAM) programme to develop a second-generation, single-dose vaccine against Japanese encephalitis ("JE") has achieved a major milestone with the start of pivotal Phase III trials.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 3
Europe
MORE ON THIS TOPIC
Job Trends
Innovation Pressure Cooker: Tackling Drug Discovery’s Biggest Challenges
April 2, 2026
·
5 min read
·
Angela Gabriel
Layoffs
Layoffs at Novo’s Ex-Catalent Site Despite Signs of Turnaround, Continued Investment
April 1, 2026
·
2 min read
·
Nick Paul Taylor
Approvals
Eli Lilly’s Oral Obesity Pill Approved, Kicking Off Renewed Novo Rivalry
April 1, 2026
·
3 min read
·
Heather McKenzie
Podcast
Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes
April 1, 2026
·
1 min read
·
Heather McKenzie
